stockrowBiogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024.
- Revenue
- +10.6%
- EPS
- −104.4%
- Free cash flow
- −69.3%
- Total debt
- +16.0%
Quarter to September 2026, against a year earlier
Follow BIIB
Alert me
Biogen Inc. (BIIB) Shares outstanding
Biogen Inc.'s shares outstanding at the end of fiscal 2025 was $147.1M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $147.8M. Over the past ten years it has ranged from $145.6M (fiscal 2023) to $231.2M (fiscal 2015); the current reading is higher than 36% of that period. Biogen Inc. ranks 16th of 20 Drug Manufacturers General companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $147.1M | 0.82% |
| FY2024 | $145.9M | 0.21% |
| FY2023 | $145.6M | (0.27%) |
| FY2022 | $146.0M | (2.41%) |
| FY2021 | $149.6M | (7.25%) |
| FY2020 | $161.3M | (13.93%) |
| FY2019 | $187.4M | (8.72%) |
| FY2018 | $205.3M | (3.62%) |
| FY2017 | $213.0M | (2.65%) |
| FY2016 | $218.8M | (5.36%) |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $147.8M | (0.61%) |
| Jun 2026 | $148.7M | 0.20% |
| Mar 2026 | $148.4M | 0.88% |
| Dec 2025 | $147.1M | 0.00% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| PFE Pfizer Inc. compare | $5.8B |
| NVO Novo Nordisk A/S compare | $4.4B |
| SNY Sanofi compare | $2.4B |
| BMY Bristol Myers Squibb Company compare | $2.1B |
| GSK GSK PLC Sponsored ADR compare | $2.0B |
| AZN AstraZeneca PLC compare | $1.6B |
| GILD Gilead Sciences, Inc. compare | $1.3B |
| AMGN Amgen Inc. compare | $546.0M |
| BIIB Biogen Inc. | $147.8M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on BIIB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement